Sarah Teichmann, the incumbent chair in stem cell medicine at Cambridge University, UK, and vice president of translational research at GSK Plc, has been appointed to the scientific advisory board of OMass Therapeutics. She will help support the company’s drug discovery platform comprising a pipeline of small molecule therapeutics in rare diseases and immunological conditions that target solute carriers, complex-bound proteins and GPCRs. Dr Teichmann brings expertise in protein interactions especially in the context of the immune system. She holds a PhD from the MRC Laboratory of Molecular Biology and Trinity College, Cambridge and is a fellow of the UK’s Academy of Medical Sciences and of the Royal Society.
OMass announced the appointment on 8 April 2024,
Copyright 2024 Evernow Publishing Ltd.